Clinical trial
Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S…
NCT00062907 · Corixa Corporation, Industry · Unknown status
Key facts
| NCT number | NCT00062907 |
|---|---|
| Title | Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer |
| Official title | Phase I Open-Label Dose Escalation Trial Evaluating The Safety And Immunogenicity Of Sequential Administration Of Recombinant DNA And Adenovirus Expressing L523S Protein In Patients With Early Stage Non-Small Cell Lung Cancer |
| Lead sponsor | Corixa Corporation, Industry |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Biological |
| Interventions | Recombinant DNA- pVAX/L523S, Recombinant adenovirus- Ad/L523S |
| Enrollment | 9 |
| Start date | May 1, 2003 |
| First posted | Jun 19, 2003 |
| Last update posted | Dec 6, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- 10–99 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: